Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Mulls Options As Medicare Shuns Alzheimer's Diagnostic-Reuters


Monday, 30 Sep 2013 03:30pm EDT 

Reuters reported that Eli Lilly And Co said the federal government has unfairly blocked patient access to its Amyvid diagnostic test for Alzheimer's disease by denying reimbursement for such products, and said a requested new study of the test could create additional delay. The U.S. Centers for Medicare & Medicaid Services (CMS), the agency that runs Medicare, on Friday determined that there was insufficient evidence that the type of radioactive imaging test "is reasonable and necessary" for diagnosing and helping treat dementia. CMS said it would consider coverage for the test only in limited circumstances: for clinical trials that must be approved in advance by the agency. Lilly said the decision denies appropriate patient access to the test, and conflicts with the National Alzheimer's Plan, a sweeping effort to find an effective way to prevent or treat Alzheimer's by 2025 and improve care of those already inflicted. The radioactive drug is used with positron emission tomography, or PET, imaging to detect levels in the brain of beta amyloid, a protein that creates brain plaques believed to be a leading cause of the progressive memory-robbing disease. 

Company Quote

65.49
 --
29 Oct 2014